AI chatbot aims to ease financial burden for rural cancer patients

NCT ID NCT07410689

First seen Feb 17, 2026 · Last updated Jun 19, 2026 · Updated 20 times

Summary

This study tests a new chatbot designed to help cancer patients and their caregivers in rural areas find clear information about insurance, travel costs, and other financial aspects of cancer care. About 60 participants will be randomly assigned to use either a hybrid chatbot or an AI-enabled chatbot. The goal is to see how helpful, usable, and trustworthy the chatbot is.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Huntsman Cancer Institute/ University of Utah

    Salt Lake City, Utah, 84112, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

AI-based hybrid chatbot

What this could lead to

If successful, this chatbot could provide a practical tool to help rural cancer patients and caregivers navigate insurance, travel costs, and other financial burdens.

What could go wrong

This is a small, early-stage pilot study with only 60 participants. The chatbot may not be helpful or easy to use for everyone, and results may not apply to broader populations.

Conditions

The condition(s) this trial relates to.

cancer Financial Stress neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.